ACRS Earnings Forecast
Looking ahead, ACRS remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 1.94M and an EPS of -0.14.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 40.89%, while EPS estimates have been Revise Downward by -8.82%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 33.72% . These revisions correlate with a 37.44% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ACRS long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Revenue Estimates for FY2025
Revise Upward
+40.89%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-8.82%
In Past 3 Month
Unlock the reason behind revisions!
Revenue Estimates for Q4 2025
Revise Upward
+33.72%
In Past 3 Month
Stock Price
Go Up
+37.44%
In Past 3 Month
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how ACRS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ACRS sees a -2.63% change in stock price 10 days leading up to the earnings, and a -4.16% change 10 days following the report. On the earnings day itself, the stock moves by -0.77%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 0.44% on the day following the earnings release and then changed by 8.85% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of ACRS's latest earnings report for ?
ACRS reported its earnings on 2025-11-05, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.13 by 0% . The stock experienced a -4.24% price change on the earnings day and a -9.75% change over the next five days, reflecting market reactions to the results.
How did ACRS's stock price react after the earnings release?
Following ACRS's earnings announcement on 2025-11-05, the stock price moved by -4.24% on the day of the release. Over the subsequent five days, it saw a -9.75% change. Historically, ACRS's stock price tends to shift by an average of -2.63% in the 10 days leading up to earnings and -4.16% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for ACRS for 2025/Q4?
For 2025/Q4, analysts estimate ACRS’s annual revenue to reach 1.94M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 40.89% and EPS estimates Revise Upward by 33.72% over the past three months, indicating analyst expectation in the company’s performance.
How does ACRS's stock price correlate with earnings forecast revisions?
The correlation between ACRS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 40.89%, while EPS estimates moved Revise Upward by 33.72% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from ACRS's next earnings report?
Based on historical trends, ACRS's stock price typically moves by -2.63% in the 10 days before its earnings and -4.16% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.14 and revenue of 1.94M.
What is the sentiment in Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Summary?
The earnings call summary and Q&A reveal multiple concerns: regulatory risks for ATI-2138, competitive pressures in the atopic dermatitis market, decreased cash reserves, and lack of clear guidance on study timelines. While there are potential synergies with ITK and JAK3 inhibitors, uncertainties in strategic direction and financial sustainability overshadow positive aspects. Without a market cap, the overall sentiment leans negative due to these uncertainties and lack of strong positive catalysts.